GlobalData: Irritable bowel syndrome risk predominant in younger, middle-aged adults

Irritable bowel syndrome (IBS) is a chronic relapsing gastrointestinal disorder, and is predominant in younger and middle-aged adults. IBS gradually declines with increasing age of the population, according to GlobalData, a leading data and analytics company.

In 2016, adults aged between 40–49 years made up the highest proportion of diagnosed prevalent cases of IBS, followed by adults aged between 30–39 years. Patients aged 80 years and older accounted for the fewest diagnosed prevalent cases of IBS (5.17%) in the seven major markets (7MM).

The US had a strong trend of increase in diagnosed prevalent cases of IBS up until the ages of 40–49 years, followed by strong downward trend in diagnosed prevalent cases. The five European countries (5EU) showed a slight increase in diagnosed IBS cases until ages 50–59 years, followed by slight decline.

While the exact cause of IBS is unknown, sensitivity of the gut and problems digesting food are possible factors, there are currently no medications or surgical procedures that can cure IBS. Treatment goals include managing symptoms, maintaining remission, and preventing relapse.

GlobalData epidemiologists forecast that the diagnosed prevalent cases of IBS in the 7MM, will increase from over 24 million cases in 2016, to over 25 million cases in 2026 at an annual growth rate (AGR) of 0.31% per year. In the 5EU the diagnosed prevalent cases of IBS will increase at a lower AGR of 0.20%.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Neurodivergent children face higher risk of chronic disabling fatigue by 18, study finds